Vestal Point Capital LP Purchases 740,000 Shares of Voyager Therapeutics, Inc. (NASDAQ:VYGR)

Vestal Point Capital LP boosted its position in Voyager Therapeutics, Inc. (NASDAQ:VYGR - Free Report) by 151.0% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,230,000 shares of the company's stock after buying an additional 740,000 shares during the period. Vestal Point Capital LP owned approximately 2.25% of Voyager Therapeutics worth $6,974,000 at the end of the most recent quarter.

A number of other institutional investors have also bought and sold shares of the company. Raymond James Financial Inc. acquired a new stake in Voyager Therapeutics during the fourth quarter worth approximately $746,000. Allspring Global Investments Holdings LLC boosted its holdings in shares of Voyager Therapeutics by 23.9% during the 4th quarter. Allspring Global Investments Holdings LLC now owns 39,313 shares of the company's stock worth $223,000 after buying an additional 7,573 shares in the last quarter. Rhumbline Advisers grew its position in shares of Voyager Therapeutics by 3.4% during the 4th quarter. Rhumbline Advisers now owns 71,497 shares of the company's stock worth $405,000 after buying an additional 2,354 shares during the period. American Century Companies Inc. grew its position in shares of Voyager Therapeutics by 8.1% during the 4th quarter. American Century Companies Inc. now owns 122,726 shares of the company's stock worth $696,000 after buying an additional 9,190 shares during the period. Finally, Wellington Management Group LLP increased its stake in shares of Voyager Therapeutics by 13.9% in the 4th quarter. Wellington Management Group LLP now owns 261,251 shares of the company's stock valued at $1,481,000 after acquiring an additional 31,882 shares in the last quarter. Institutional investors own 48.03% of the company's stock.

Voyager Therapeutics Stock Performance

NASDAQ:VYGR traded down $0.16 on Thursday, hitting $2.99. The stock had a trading volume of 342,931 shares, compared to its average volume of 442,228. Voyager Therapeutics, Inc. has a 1 year low of $2.75 and a 1 year high of $9.55. The firm's fifty day simple moving average is $3.37 and its two-hundred day simple moving average is $4.71. The stock has a market cap of $165.45 million, a P/E ratio of 4.21 and a beta of 0.95.

Voyager Therapeutics (NASDAQ:VYGR - Get Free Report) last released its earnings results on Tuesday, May 6th. The company reported ($0.53) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.35) by ($0.18). The business had revenue of $6.47 million during the quarter, compared to the consensus estimate of $13.55 million. Voyager Therapeutics had a net margin of 15.80% and a return on equity of 8.33%. Equities research analysts predict that Voyager Therapeutics, Inc. will post -0.91 EPS for the current year.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on VYGR. HC Wainwright reissued a "buy" rating and set a $30.00 target price on shares of Voyager Therapeutics in a research note on Tuesday, April 8th. Canaccord Genuity Group dropped their price objective on shares of Voyager Therapeutics from $14.00 to $12.00 and set a "buy" rating on the stock in a report on Thursday, March 13th. Wedbush reissued an "outperform" rating on shares of Voyager Therapeutics in a research report on Wednesday, March 12th. Wells Fargo & Company set a $10.00 target price on Voyager Therapeutics and gave the company an "overweight" rating in a research report on Wednesday, March 12th. Finally, Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Voyager Therapeutics in a research note on Wednesday, March 12th. One analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Buy" and an average target price of $13.39.

Insiders Place Their Bets

In related news, CEO Alfred Sandrock sold 10,885 shares of the business's stock in a transaction dated Wednesday, April 2nd. The shares were sold at an average price of $3.43, for a total value of $37,335.55. Following the transaction, the chief executive officer now directly owns 430,931 shares of the company's stock, valued at approximately $1,478,093.33. The trade was a 2.46% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 6.39% of the company's stock.

Voyager Therapeutics Company Profile

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.